The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZVRA | -11.26% | -52.1% | -13.68% | -95% |
| S&P | +14.18% | +88.25% | +13.47% | +225% |
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $26.06M | 605.4% |
| Gross Profit | $24.51M | 1484.7% |
| Gross Margin | 94.04% | 141.9% |
| Market Cap | $533.84M | 46.2% |
| Market Cap / Employee | $9.05M | 0.0% |
| Employees | 59 | -14.5% |
| Net Income | -$0.54M | 98.4% |
| EBITDA | $4.54M | 117.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $54.44M | 0.7% |
| Accounts Receivable | $16.03M | 105.7% |
| Inventory | 1.4 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $62.28M | 4.9% |
| Short Term Debt | $0.44M | -18.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 15.30% | 66.7% |
| Return On Invested Capital | -120.85% | 77.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.16M | 122.9% |
| Operating Free Cash Flow | $4.71M | 126.0% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 15.08 | - | |||
| Price to Book | 6.36 | 10.13 | 11.74 | 4.47 | -15.60% |
| Price to Sales | 18.96 | 9.98 | 7.78 | 6.31 | -52.90% |
| Price to Tangible Book Value | -80.14 | -11.81 | -15.51 | 4.97 | -107.45% |
| Enterprise Value to EBITDA | -31.84 | -108.91 | -32.06 | 87.17 | -763.13% |
| Return on Equity | -207.8% | -204.8% | 3.5% | 34.8% | -128.13% |
| Total Debt | $60.30M | $61.84M | $62.28M | $62.72M | 4.66% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
